Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rizatriptan in acute migraine attacks among patients receiving topiramate prophylaxis
2008-008283-26Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rizatriptan in migraine (2 arms), sponsored by Merck & Co. Primary endpoint: Pain relief at 2 hours post-dose. Started Jan 2009; status: completed.
02
Drugs
rizatriptan
03
Conditions
migraine
Beyond the preview
Go deeper on 2008-008283-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008283-26.